Navigation Links
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
Date:3/12/2009

exposed to a very potent stimulant (TRAP-thrombin receptor agonist peptide)," said Enrico Veltri, M.D., group vice president of global clinical research, cardiovascular and metabolic disease, Schering-Plough Research Institute. "These data, along with subsequent data from Phase II acute coronary syndromes (ACS) and stroke studies conducted in Japan, suggest that TRA is a novel medication that targets a pathway to platelet aggregation not addressed by existing medications."

The 1,030-patient TRA-PCI trial was designed to evaluate the safety and tolerability of TRA in patients undergoing PCI. A secondary objective was to assess whether patients treated with the compound in addition to standard-of-care therapies had fewer cardiovascular events such as heart attack, need for urgent coronary revascularization, or death at 60 days compared to patients treated with the standard of care alone. While not powered to establish efficacy, the study did report a non-statistically significant 46 percent reduction in cardiovascular events at the highest TRA dose tested compared to standard of care alone. Preliminary results were presented in March 2007 at the American College of Cardiology/i2 Summit in New Orleans by David J. Moliterno, M.D., Chief of Cardiovascular Medicine, University of Kentucky College of Medicine, and Medical Director of the Linda and Jack Gill Heart Institute, on behalf of the TRA-PCI investigators.

Study Design

The Phase II TRA-PCI trial was a multinational, randomized, double-blind, placebo-controlled dose-ranging trial assessing both oral loading doses as well as maintenance doses of Schering-Plough's TRA. The trial enrolled 1,030 patients 45 years or older, with coronary artery disease for whom PCI was planned, and randomized to one of three oral loading doses of TRA (10mg, 20mg or 40mg) or placebo in a 3:1 ratio of active drug to placebo. The loading doses were increased in a sequential fas
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
2. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
3. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
4. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
5. Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting
6. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
7. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
11. Berlin Hearts EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Kan. , July 25, 2014 /PRNewswire-iReach/ -- ... and TCGRx, of Powers Lake, Wisconsin ... partners in a distribution and co-marketing agreement allowing ... retail pharmacies throughout the United States ... robotics-based pharmacy management and workflow systems to retail ...
(Date:7/25/2014)... , July 25, 2014  CVS Caremark Corporation (NYSE: ... call on Tuesday, August 5, 2014, at 8:30 a.m. ... quarter 2014 financial results. An audio webcast ... the Investor Relations portion of the CVS Caremark website ... http://info.cvscaremark.com/investors . This webcast will be archived and ...
(Date:7/25/2014)... Trinidad and Tobago , July 25, 2014 ... the Trinidad & Tobago Ministry of Health approved ... therapy that significantly increases the cure rate from ... infected with the genotype 1 virus. Telaprevir is ... the trade brand INCIVO®. Photo - ...
Breaking Medicine Technology:ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3
... The University of Oxford Clinical Trial,Service Unit ... results of the SEAS trial of ezetimibe should ... the SHARP and,IMPROVE-IT trials of ezetimibe, and reporting ... independently of the drug,manufacturers., The two hypothesis-testing ...
... clinicians identify risk in patients, including ... BIRMINGHAM, Ala., July 21 Using the ... link between,adiponectin and heart disease progression. The information ... cholesterol and heart,disease risk-lowering treatments in at-risk patients., ...
Cached Medicine Technology:Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 2Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 3VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis 2VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis 3
(Date:7/25/2014)... (HealthDay News) -- Shift workers, especially men, may be at ... on such schedules, a new study suggests. Also at ... set schedule, with shifts moving around at various times of ... said one expert, Dr. Alan Manevitz, a clinical psychiatrist at ... long known that working shifts disrupts many key body chemicals, ...
(Date:7/25/2014)... The American Society of Anesthesiologists (ASA) today announced ... (PSH) Learning Collaborative, a national initiative designed to ... surgery. More than 40 leading health care ... the collaborative, which will convene for the first ... July 25-26, in Schaumburg, Ill. , The PSH ...
(Date:7/25/2014)... 25, 2014 In today’s technological era, ... and supporting devices. This benefits the organization in various ... cyber attacks which can destroy the confidential information and ... Risk and Compliance (EGRC) manage and protect the enterprise ... can cause loss in dollars to the comp may. ...
(Date:7/25/2014)... Dallas, TX (PRWEB) July 25, 2014 ... Market Outlook to 2020” provides company shares and ... categories, and global corporate-level profiles of the key ... related to the Laryngoscopes market wherever available. , ... dynamic market forecast models. Rsearcher uses epidemiology and ...
(Date:7/25/2014)... A protein that controls when genes are switched on ... of the brain to regulate metabolism, UT Southwestern Medical ... to new therapies to treat obesity and diabetes, since ... 1 (Xbp1s) appears to influence the body,s sensitivity ... hormones central to the body,s regulation of food intake ...
Breaking Medicine News(10 mins):Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:ASA launches national Perioperative Surgical Home learning collaborative 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 3Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 4Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 5Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2
... for Seven Water Bodies; New Species, Water Body Added , ... fish consumption advisories that include two new fish species and ... list, but also eases or lifts advisories on fish from ... an interagency partnership between the Pennsylvania Fish and Boat Commission ...
... ... to serve more effectively millions of people suffering from alcohol abuse worldwide.....read more... ... ... has completely redesigned its website to serve more effectively millions of people suffering ...
... ... its highly acclaimed Restore® program, which provides immediate support and practical advice to family ... ... Alcohol Recovery (NIFAR®) is introducing a new version of its highly acclaimed Restore® ...
... sooner, with no fasting, , TUESDAY, Dec. 29 (HealthDay News) ... Diabetes Association is promoting a more prominent role for the ... diabetes and prediabetes. , Long used in the management of ... for the previous two to three months. The new guidelines ...
... , Health gurus say recommit each Monday until the habit ... January 1st millions of Americans will resolve to quit smoking -- again. ... Johns Hopkins and the American Cancer Society say it doesn,t have to ... agree, just quit again the following Monday. And recommit to stay quit ...
... 29 Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), ... a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system ... today provided a business update, and management reiterated its ... Echo completes the development and regulatory review of its ...
Cached Medicine News:Health News:Updated Fish Consumption Advisories Issued for 2010 2Health News:Updated Fish Consumption Advisories Issued for 2010 3Health News:New NIFAR Website Offers Millions a Comprehensive Resource for Alcohol Education, Recovery, and Support 2Health News:New NIFAR Website Offers Millions a Comprehensive Resource for Alcohol Education, Recovery, and Support 3Health News:Innovative Program Gives Instant Support to Millions who are Living and Suffering with a Problem Drinker 2Health News:Innovative Program Gives Instant Support to Millions who are Living and Suffering with a Problem Drinker 3Health News:New Guidelines Urge A1C Test for Diabetes Diagnosis 2Health News:This New Years, Smokers Get 52 Chances to Stay Quit 2Health News:Echo Therapeutics Provides Business Update 2Health News:Echo Therapeutics Provides Business Update 3Health News:Echo Therapeutics Provides Business Update 4Health News:Echo Therapeutics Provides Business Update 5
... Mapping. Biosense Webster offers a complete ... SANTORO Fixed Catheter is designed for ... the coronary sinus. The pair of ... tip permit pacing in the coronary ...
Standard Deflectable Catheters...
... Soft HIS diagnostic catheters provide ... designed curve that allows for ... HIS bundle. In addition, the ... reduce the risk of perforation ...
The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures....
Medicine Products: